8-K: Heron Therapeutics Reports Q4 2024 GAAP Net Income of $3.6 Million and Full-Year Revenue Up 14%

Heron Therapeutics announces positive Q4 2024 results, driven by strong revenue growth and strategic corporate updates.

Summary

• Heron Therapeutics reported a GAAP net income of $3.6 million for Q4 2024.
• The company's full-year 2024 net revenue reached $144.2 million, a 14% increase year-over-year.
• Adjusted EBITDA for the full year 2024 was $8.6 million.
• ZYNRELEF generated $8.5 million in net revenue during Q4 2024, and the ZYNRELEF Vial Access Needle (VAN) was launched in December 2024.
• A U.S. District Court ruled in favor of Heron in a patent lawsuit against Fresenius Kabi USA, LLC, upholding the validity of CINVANTI patents until 2035.
• Net revenue for 2025 is projected to be between $153.0 million and $163.0 million.
• Adjusted EBITDA for 2025 is expected to be between $0.0 million and $8.0 million.
• Cash, cash equivalents, and short-term investments totaled $59.3 million as of December 31, 2024.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the company achieving profitability in Q4, revenue growth, and a favorable legal outcome; however, the full-year loss and uncertain adjusted EBITDA guidance for 2025 temper the overall outlook.

Positives

• The company achieved GAAP net income of $3.6 million in Q4 2024.
• Full-year 2024 net revenue increased by 14% to $144.2 million.
• Adjusted EBITDA for 2024 was positive at $8.6 million.
• ZYNRELEF revenue increased, and the VAN launch is expected to simplify preparation and reduce withdrawal time.
• The company won a patent lawsuit, securing CINVANTI patent protection until 2035.
• The partnership with Crosslink Network is expected to expand the promotional effort for ZYNRELEF.
• Expanded label indications for ZYNRELEF cover an estimated 17 million annual targeted procedures.
• ZYNRELEF will continue to receive separate payment from April 1, 2025, until at least the end of 2027.
• APONVIE net revenue increased 224.8% from 2023 to 2024.
• Acute Care net revenue increased 57.3% from 2023 to 2024.

Negatives

• The company reported a net loss of $13.580 million for the full year 2024.
• The adjusted EBITDA guidance for 2025 is between $0.0 million and $8.0 million, indicating potential for no profit.
• SUSTOL net revenue decreased 7.4% for the quarter ended December 31, 2024.

Risks

• The company cautions that forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• The company's future performance depends on the successful commercialization of its products.
• The company's financial guidance is subject to change based on various factors.
• The company may be required to write-off additional inventory in the future.
• Future equity financings may be needed.
• There is a risk of inability or delay in achieving profitability.

Future Outlook

The company anticipates transformational growth for ZYNRELEF in 2025, driven by expanded label indications, the launch of the VAN, the approval of the NOPAIN Act, and the enhanced promotional reach of the Crosslink relationship; net revenue for 2025 is projected to be between $153.0 million and $163.0 million, and adjusted EBITDA is expected to be between $0.0 million and $8.0 million.

Management Comments

• Craig Collard, Chief Executive Officer, stated that 2024 was a milestone year for Heron.
• Craig Collard, Chief Executive Officer, stated that Zynrelef is poised for transformational growth in 2025.

Industry Context

Heron's focus on postoperative pain management and CINV prevention aligns with the broader industry trend of seeking non-opioid pain relief solutions and improving patient outcomes in oncology; the successful defense of CINVANTI patents is crucial in maintaining market share in the antiemetic market.

Comparison to Industry Standards

• Heron's ZYNRELEF competes with traditional local anesthetics like bupivacaine and aims to provide superior pain relief and reduce opioid use, similar to efforts by companies like Pacira BioSciences with EXPAREL.
• In the CINV market, CINVANTI competes with oral aprepitant (EMEND) and other NK1 receptor antagonists, with Heron emphasizing the convenience and efficacy of its IV formulation.
• The company's focus on non-opioid pain management aligns with the broader healthcare industry's efforts to reduce opioid dependence, a trend supported by regulatory initiatives and public health campaigns.

Legal Proceedings

• A U.S. District Court ruled in favor of Heron in a patent lawsuit against Fresenius Kabi USA, LLC, upholding the validity of CINVANTI patents which expire in 2035.

Stakeholder Impact

• Shareholders will benefit from the improved financial performance and the potential for future growth.
• Employees will be impacted by the company's strategic initiatives and the potential for increased job security.
• Patients will benefit from the availability of innovative therapies for pain management and CINV prevention.
• The company's suppliers and partners will be impacted by the company's financial performance and strategic decisions.

Next Steps

• Heron will host a conference call and live webcast on February 27, 2025, to discuss the financial results.
• The company will continue to focus on the commercialization of its products and the expansion of ZYNRELEF's market reach.
• Heron will continue to pursue opportunities to develop and commercialize therapeutic innovations.

Key Dates